Cat's Claw

Una de Gato's primary bioactives—pentacyclic oxindole alkaloids (POA) such as pteropodine, isopteropodine, and mitraphylline—modulate immunity by inhibiting NF-κB activation, suppressing TNF-alpha and IL-1 cytokines, and blocking COX-1/COX-2 enzyme activity, while quinovic acid glycosides drive apoptosis in cancer cell lines. In a small human pilot study, 350 mg daily of aqueous extract for six weeks elevated white blood cell counts by approximately 9%, and preclinical data show that mitraphylline at 30 mg/kg reduces TNF-alpha by 50% and IL-1alpha/beta by 70% in animal models.

Origin & History

Uncaria tomentosa is a woody climbing vine native to the tropical rainforests of South and Central America, particularly the Amazonian regions of Peru, Brazil, Colombia, and Bolivia, thriving at elevations between 200–800 meters in humid, dense jungle canopy. The plant is named for its distinctive hook-like thorns resembling cat claws, which it uses to anchor itself to host trees and can grow to lengths exceeding 30 meters. Traditional cultivation centers around the Chanchamayo and Nevati river valleys of Peru's Junín region, where indigenous communities have harvested the inner bark and root bark for centuries using sustainable, rotational methods.

Historical & Cultural Context

Una de Gato has been integral to Amazonian ethnomedicine for at least several centuries, with documented use by indigenous peoples of Peru—including communities near Chanchamayo, Nevati, and Puerto Bermez in the Junín department—who employed decoctions of the inner bark to treat inflammation, wounds, immune disorders, cancer, arthritis, and infections including what they described as AIDS-like wasting conditions. The vine holds spiritual and ceremonial significance in some Amazonian traditions, where its preparation and administration were ritually governed by healers (curanderos), and the preparation method—boiling bark in water for an extended period—was considered essential to extracting the plant's curative spirit alongside its chemical constituents. Scientific investigation began in earnest in the 1980s when European researchers, particularly from Austria and Germany, isolated and characterized the oxindole alkaloid fraction and documented immunomodulatory activity, triggering a rapid expansion of commercial interest and export from Peru. The plant's cultural cachet as an Amazonian anti-cancer and immune tonic drove widespread adoption in European and North American herbal markets through the 1990s and 2000s, with Peru subsequently regulating wild harvest to prevent overharvesting of wild populations.

Health Benefits

- **Immunomodulation**: Aqueous extracts containing pentacyclic oxindole alkaloids stimulate white blood cell production and activity, increase lysozyme secretion, enhance antibody levels, and boost melanomacrophage function, supporting a broadly activated innate immune response.
- **Anti-Inflammatory Activity**: Quinovic acid glycosides and oxindole alkaloids together inhibit NF-κB activation at 500 μg/ml in Jurkat T cells and suppress iNOS gene expression and nitrite formation at 50–200 μg/ml, reducing LPS-induced pro-inflammatory cytokine production by 70–75%.
- **Potential Anticancer Properties**: POA-rich extracts demonstrate selective cytotoxicity to several cancer cell lines while sparing normal cells at moderate doses; quinovic acid glycosides specifically induce apoptosis in T24 bladder cancer cells through direct caspase pathway engagement.
- **Antioxidant and Cytoprotection**: Proanthocyanidins including epicatechin, procyanidins B1/B2/B4, and cinchonain neutralize reactive oxygen species, while the extract attenuates peroxynitrite-induced apoptosis at 100 μg/ml, protecting cellular integrity under oxidative stress conditions.
- **Platelet Aggregation Inhibition**: Indole alkaloids rhynchophylline and isorhynchophylline antagonize platelet-activating factor (PAF) and thromboxane receptor signaling, reducing platelet aggregation and offering potential cardiovascular protection.
- **Antiviral and Antimicrobial Support**: In silico molecular docking and molecular dynamics simulations identify speciophylline, cadambine, and proanthocyanidin B2 as strong binding candidates to the SARS-CoV-2 3CLpro cysteine protease, suggesting a mechanism for antiviral activity warranting further investigation.
- **Gastrointestinal and Connective Tissue Support**: Traditional and preliminary evidence indicates that COX inhibition and anti-inflammatory alkaloids reduce intestinal inflammation, while beta-sitosterol and oleanolic acid contribute to mucosal integrity and connective tissue repair.

How It Works

Pentacyclic oxindole alkaloids (POA), particularly mitraphylline and isopteropodine, suppress nuclear factor-kappa B (NF-κB) activation—nearly completely at 500 μg/ml—thereby downregulating transcription of pro-inflammatory genes encoding TNF-alpha, IL-1alpha, IL-1beta, and inducible nitric oxide synthase (iNOS), resulting in measurable reductions in nitrite formation and cytokine output in macrophage and T-cell models. Quinovic acid glycosides exert cytostatic and pro-apoptotic effects in malignant cell lines, including T24 bladder carcinoma cells, via direct interference with cell cycle progression and activation of intrinsic apoptotic cascades, while leaving non-cancerous cell lines largely unaffected at equivalent concentrations. Rhynchophylline and isorhynchophylline inhibit platelet-activating factor and block thromboxane A2 receptor signaling, reducing platelet aggregation in a receptor-competitive manner. The proanthocyanidin fraction—comprising epicatechin, cinchonain, and procyanidins A1/B1/B2/B4—scavenges peroxynitrite and superoxide radicals, providing a complementary antioxidant mechanism that synergizes with the alkaloid-mediated cytoprotective effects.

Scientific Research

The evidence base for Una de Gato consists predominantly of in vitro cell studies and small-scale animal experiments, with very limited controlled human trial data, placing it firmly in the preliminary-to-moderate evidence tier. The most cited human data involve a pilot study of only four healthy volunteers receiving 350 mg/day aqueous extract for six weeks, which demonstrated a ~9% increase in white blood cell counts—an outcome replicated in subsequent slightly larger follow-up cohorts but still lacking large randomized controlled trial confirmation. Preclinical evidence is more robust: dose-dependent anti-inflammatory effects (mitraphylline 30 mg/kg, i.p.) reducing TNF-alpha by 50% and IL-1 by 70% in murine models are well-documented, and in vitro NF-κB and COX inhibition studies provide mechanistic plausibility, but translation to standardized human clinical outcomes remains largely unvalidated. No large multicenter RCTs with pre-registered endpoints, standardized extract doses, and peer-reviewed effect sizes have been published as of the available literature, and the heterogeneity of extract types (POA vs. TOA vs. aqueous vs. hydroalcoholic) makes cross-study comparison difficult.

Clinical Summary

Human clinical investigation of Uncaria tomentosa remains in early stages, with the most substantive data derived from small unblinded pilot studies. A six-week pilot in healthy adults using 350 mg/day aqueous extract showed approximately 9% elevation in circulating leukocyte counts, supporting traditional immunostimulatory claims, though the absence of placebo controls and small sample size (n=4) limits conclusions. Preclinical animal and cell culture models consistently demonstrate dose-dependent suppression of NF-κB, TNF-alpha, IL-1, and COX activity, alongside selective pro-apoptotic effects in cancer cell lines, but these findings have not yet been confirmed in adequately powered phase II or III human trials. Confidence in the current clinical evidence is low to moderate; the totality of data supports plausibility and traditional use, but prescriptive clinical recommendations await rigorous RCT-level confirmation.

Nutritional Profile

Una de Gato inner bark is not a significant source of macronutrients (proteins, fats, or carbohydrates) in supplemental doses and is consumed primarily for its phytochemical content rather than nutritional value. Total oxindole alkaloids range from 0.15–4.60% in crude dried bark, with POA-enriched hydroalcoholic extracts reaching up to 5.61%; aqueous extracts yield approximately 0.26% alkaloids, reflecting the differential solubility of these nitrogen-containing compounds. The triterpene fraction includes quinovic acid glycosides (tomentosides), ursolic acid, and oleanolic acid, while sterols beta-sitosterol and stigmasterol are present in minor quantities. The polyphenol fraction—comprising epicatechin, procyanidins A1/B1/B2/B4, and cinchonain—contributes antioxidant activity that is water-extractable and bioavailable through standard decoction; flavonoids and quinones are also present but at lower concentrations not yet precisely quantified in standardized analytical studies. Bioavailability of alkaloids is enhanced in hydroalcoholic preparations relative to aqueous decoctions due to greater organic solubility of POA compounds.

Preparation & Dosage

- **Traditional Decoction**: Boil 20 g of sliced inner root bark in 1 liter of water for 45 minutes; strain and consume as a tea, traditionally used 1–3 times daily for therapeutic purposes by Amazonian indigenous communities.
- **Aqueous Extract (Standardized)**: 350 mg/day in the primary human pilot study; typical commercial capsule doses range from 250–500 mg standardized aqueous extract, taken 1–2 times daily with meals.
- **Hydroalcoholic (Ethanolic) Extract**: Contains approximately 5.61% total oxindole alkaloids; doses of 300–600 mg standardized extract reported in commercial preparations.
- **POA-Standardized Extract**: Standardized to 90–110% of labeled pentacyclic oxindole alkaloid content on a dried weight basis; preferred over TOA-dominant extracts for immunological applications per some researchers.
- **Bark Powder (Crude)**: 1–4 g per day encapsulated root bark; lower bioavailability of alkaloids than standardized extracts due to variable alkaloid concentration (0.15–4.60% in raw bark).
- **Timing and Cycling**: No formal cycling protocol established; traditional and modern use suggests continuous use for 4–8 weeks followed by assessment; take with food to reduce potential gastrointestinal upset.

Synergy & Pairings

Una de Gato is frequently combined with other anti-inflammatory botanicals such as Boswellia serrata (boswellic acids inhibiting 5-LOX) and turmeric (curcumin inhibiting NF-κB at the IKK level), creating a multi-pathway anti-inflammatory stack that may address COX, LOX, and NF-κB signaling simultaneously with potentially lower individual doses required for effect. In immune-support formulations, pairing with elderberry (Sambucus nigra, anthocyanin-mediated cytokine modulation) or astragalus (Astragalus membranaceus, polysaccharide-driven macrophage activation) may complement the POA-mediated leukocyte stimulation of cat's claw through distinct but additive immunological mechanisms. For antioxidant synergy, co-administration with vitamin C enhances proanthocyanidin stability and bioavailability in aqueous preparations, as ascorbic acid prevents oxidative degradation of the procyanidin fraction, a pairing with historical precedent in South American herbal traditions.

Safety & Interactions

At typical supplemental doses (250–500 mg/day standardized extract), Una de Gato is generally well-tolerated, with mild gastrointestinal side effects—nausea, diarrhea, and abdominal discomfort—the most frequently reported adverse events; in vitro data confirm that POA-rich and crude aqueous extracts become cytotoxic to normal cells only at concentrations substantially exceeding therapeutic ranges. Clinically significant drug interactions include potentiation of anticoagulant and antiplatelet agents (warfarin, clopidogrel, aspirin) due to rhynchophylline- and isorhynchophylline-mediated platelet aggregation inhibition, and theoretical additive effects with NSAIDs and corticosteroids via NF-κB and COX pathway overlap—caution and dose reduction of concurrent medications is advisable. Uncaria tomentosa is contraindicated during pregnancy based on historical use as an abortifacient and animal data suggesting uterotonic properties; it should also be avoided during lactation due to insufficient safety data. The European Medicines Agency (EMA) has assessed standardized preparations as acceptably safe for short-term adult use, but no maximum tolerated dose in humans has been formally established; immunosuppressed individuals and organ transplant recipients should consult a physician before use due to immunostimulatory activity.